Structure Therapeutics Reports Best-in-Class Oral GLP-1 Agonist Data – Major Phase 2 Results for Aleniglipron

Key Highlights from the ACCESS II Trial and Strategic Updates – Significant Positive Catalyst for Investors

Summary of Results

• Topline Phase 2 Data: Structure Therapeutics (NASDAQ: GPCR) announced exceptionally strong results from its Phase 2 ACCESS II trial evaluating its once-daily, oral small molecule GLP-1 receptor agonist, aleniglipron, for obesity and overweight patients.
• Unmatched Oral Efficacy: At 44 weeks, aleniglipron achieved placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16.0% (37 lbs) at the 240 mg dose, with no evidence of a weight loss plateau. This efficacy is described as the highest observed among oral GLP-1RAs and is comparable to leading injectable therapies.
• Sustained and Increasing Weight Loss: In the ACCESS Open Label Extension (OLE) study, the 120 mg dose continued to show weight loss of 16.2% (40.5 lbs) at 56 weeks, again with no sign of plateauing.
• Improved Tolerability & Safety: Updated interim data show low rates of discontinuation due to adverse events (AEs): just 2.0–3.4% with the lower 2.5 mg starting dose, and only one (3.7%) AE-related discontinuation in higher dose groups. No off-target events, drug-induced liver injury, or QTc prolongation were observed across more than 625 participants.
• Next Steps: End-of-Phase 2 meeting with the FDA is scheduled for Q2 2026. Phase 3 studies are planned to begin in the second half of 2026, with a starting titration dose of 2.5 mg and escalation up to 240 mg.

Detailed Results and Clinical Program Update

ACCESS II Trial Design

• Randomized, double-blind, placebo-controlled study in adults with obesity or overweight (BMI >25 kg/m² and at least one weight-related comorbidity).
• 85 participants; 44-week treatment; titration from 5 mg up to 120 mg, 180 mg, or 240 mg.
• All three dose cohorts met statistical significance for weight loss versus placebo at 36 and 44 weeks.

Key Efficacy Data (44 Weeks)

Body Composition Study and OLE Study – Lower 2.5 mg Starting Dose

• Body composition study (n=71): Starting at 2.5 mg and titrating up to 120 mg, median 20-week follow-up showed 6.8% weight loss and improved tolerability.
• ACCESS OLE Study: Placebo crossover group started at 2.5 mg. Results at 20 weeks align with body composition findings, confirming better tolerability and continued weight loss.

Safety Profile – Key Details for Investors

• Over 625 patients exposed to aleniglipron; no drug-induced liver injury, no persistent liver enzyme elevations, and no QTc prolongation.
• Discontinuation rates due to AEs with 2.5 mg starting dose were 2.0–3.4%, significantly lower than with the 5 mg starting dose.
• Most common AEs were gastrointestinal (GI)-related (nausea, vomiting), consistent with the GLP-1RA class.

Strategic and Price-Sensitive Developments

• Phase 3 readiness: Company is on track for an End-of-Phase 2 meeting with FDA in Q2 2026 and expects to initiate Phase 3 in 2H 2026. The design will use a lower starting dose of 2.5 mg, improving tolerability — a key differentiator versus competitors.
• Market Opportunity: Aleniglipron could potentially become the first oral GLP-1RA with efficacy matching injectables, addressing the scalability and accessibility challenges of peptide therapies and opening the therapy to millions more people.
• Pipeline Expansion: Structure Therapeutics is also advancing next-generation oral small molecules, including amylin receptor agonists and combination GLP-1/GIP, glucagon, and apelin candidates, further diversifying their metabolic franchise.

Management and KOL Commentary

Raymond Stevens, Ph.D., CEO: “The totality of efficacy and tolerability data across the Phase 2 program demonstrate clear differentiation of aleniglipron, with the highest weight loss observed for an oral GLP-1RA to date and a safety profile appropriate for chronic use in a disease that impacts millions.”

Julio Rosenstock, MD, Steering Committee Chair: “The weight-lowering data from these ACCESS studies, without apparent plateau by Week 56, are encouraging… In addition, the tolerability profile of starting at a low dose of 2.5 mg and slow titration positions the program ready for Phase 3 studies.”

Investor Call Information

Structure Therapeutics will host a conference call and webcast on March 16, 2026, at 8:30 a.m. ET. Details and replay will be available on the company’s investor relations website.

Implications for Investors

• These results are highly price-sensitive and potentially transformative for Structure Therapeutics’ valuation. The data positions aleniglipron as a best-in-class oral GLP-1, with efficacy matching injectables and a safety/tolerability profile supporting chronic use.
• Near-term catalysts: Upcoming FDA meeting in Q2 2026 and anticipated Phase 3 initiation in 2H 2026 are major milestones.
• Competitive advantage: Oral, once-daily, high-efficacy GLP-1RA could disrupt the obesity and diabetes markets, especially for patients seeking oral alternatives to injectables.
• Risks: As with all clinical-stage therapies, there remains regulatory and development risk, and longer-term/larger studies are needed to confirm results.

About Structure Therapeutics

Structure Therapeutics is a clinical-stage biopharma company developing oral small molecule treatments for chronic metabolic conditions, leveraging its structure-based drug discovery platform to build a robust, scalable pipeline targeting GPCRs.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All statements regarding future plans, expectations, and potential outcomes are subject to risks and uncertainties. Investors should review the company’s SEC filings and consult professional advisors before making investment decisions.

View Structure Therapeutics Inc. Historical chart here